---
title: "Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency"
description: "Serina Therapeutics Inc. faces delisting risk from the NYSE due to a deficiency in stockholders' equity, which dropped to $1.6 million as of September 30, 2025. The company has reported losses in thre"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272745731.md"
published_at: "2026-01-15T21:03:59.000Z"
---

# Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency

> Serina Therapeutics Inc. faces delisting risk from the NYSE due to a deficiency in stockholders' equity, which dropped to $1.6 million as of September 30, 2025. The company has reported losses in three of its last four fiscal years, failing to meet the NYSE's continued listing criteria. Serina must submit a compliance plan by February 8, 2026, to regain compliance by July 9, 2027, or face potential delisting proceedings.

Serina Therapeutics Inc. has received a deficiency notification from the New York Stock Exchange (NYSE) regarding its stockholders’ equity, which fell to $1.6 million as of September 30, 2025. The company has also reported losses in three of its four most recent fiscal years, putting it below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. Serina must submit a compliance plan by February 8, 2026, outlining actions to regain compliance by July 9, 2027. Failure to submit an acceptable plan may result in delisting proceedings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000003), on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SER.US - Serina Therapeutics](https://longbridge.com/en/quote/SER.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Chief Scientific Officer Randall Moreadith Reports Sale of Serina Therapeutics Inc. Common Shares | Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported the sale of common shares of the c | [Link](https://longbridge.com/en/news/272107151.md) |
| Serina Therapeutics Inc. held annual shareholder meeting | Serina Therapeutics Inc. held its annual shareholder meeting on November 7, 2025. During the meeting, stockholders elect | [Link](https://longbridge.com/en/news/265567810.md) |
| The Most Overlooked Risk in Options Trading: Capital Drift | The Most Overlooked Risk in Options Trading: Capital Drift | [Link](https://longbridge.com/en/news/275985877.md) |
| REG - BAE SYSTEMS PLC - Dividend Timetable | BAE Systems plc has announced its dividend timetable for 2026. The final dividend ex-dividend date is set for April 23,  | [Link](https://longbridge.com/en/news/276204257.md) |
| Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares | Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported the disposal of common shares of t | [Link](https://longbridge.com/en/news/269555008.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
